Ozempic and GLP-1 Medication Lawsuits
Ozempic and other GLP-1 medications have been the subject of litigation involving reports of serious gastrointestinal complications and other alleged side effects.
If you had complications after using one of these medications, this page explains the situations people often bring to a case review.
Lawsuit Center is the intake and referral practice of David Meldofsky, a California attorney. This page is for general educational purposes only and does not create an attorney-client relationship.
What Are Ozempic Lawsuits?
These lawsuits generally involve allegations that manufacturers failed to adequately warn patients and doctors about potential risks associated with certain GLP-1 medications.
These cases are part of broader active lawsuits involving pharmaceutical products and alleged side effects.
Where the Litigation Stands
The federal gastrointestinal injury cases are consolidated as MDL 3094 in the Eastern District of Pennsylvania before Judge Karen Spencer Marston. In an MDL, each plaintiff keeps an individual case while one judge coordinates the pretrial steps.
In September 2026, the court held a five-day hearing on whether the plaintiffs' experts may testify on general causation and on the adequacy of the label warnings. The drug companies have also moved for summary judgment on the warning question. The court has not ruled. No trial has been held and no settlement has been reached.
Vision loss claims alleging a condition called NAION proceed separately in MDL 3163, created in December 2025 and also assigned to Judge Marston. Briefing there on general causation and preemption runs through August 31, 2027. State court proceedings are also pending in New Jersey and Indiana. People with sudden vision loss after one of these drugs can use the separate vision loss case review.
Lawsuit Informer keeps the case counts and a plain-language record of each development on its Ozempic lawsuit updates page.
How the Litigation Developed
- August 2023: The first gastroparesis failure-to-warn lawsuit is filed against GLP-1 manufacturers.
- February 2024: The Judicial Panel on Multidistrict Litigation consolidates the gastrointestinal cases as MDL 3094 in the Eastern District of Pennsylvania.
- Late 2024: Plaintiffs file a master complaint detailing gastroparesis, intestinal obstruction, and related injuries, and the panel adds Saxenda cases while keeping blood clot claims separate.
- 2025: The court requires objective diagnostic support, such as a gastric emptying study, for gastroparesis claims and narrows portions of the expert lineup. Filings roughly double over the year.
- December 2025: A separate MDL is created for NAION vision loss claims, MDL 3163, also before Judge Marston.
- Mid-2026: The court declines to exclude testimony from a former FDA commissioner, and the parties plan expert admissibility and summary judgment hearings. Roughly 3,800 gastrointestinal cases are pending.
- August 2026: The court sets the schedule for the vision loss MDL, with expert and summary judgment briefing on general causation and preemption due by August 31, 2027.
- September 2026: The court holds a five-day hearing, September 14 through 18, on the plaintiffs' experts on general causation and label warnings. The ruling is pending.
Who May Qualify for Review
- Individuals who used Ozempic or similar GLP-1 medications
- Patients who experienced serious gastrointestinal complications
- Those who required medical treatment related to side effects
- Individuals trying to determine whether their experience fits a broader pattern seen in similar claims
Whether a person may qualify depends on the facts of the situation, including medication history, timing, reported complications, treatment required, and other case-specific details.
Request a Case ReviewReported Complications
- Severe gastrointestinal issues
- Stomach paralysis, often referred to as gastroparesis
- Persistent nausea or vomiting
- Other digestive complications
This information is general and educational. It is not a statement that any specific complication was caused by a medication in any individual case.
Why People Are Exploring Claims
People often begin exploring these claims after experiencing severe complications following use of a GLP-1 medication and wanting to better understand whether similar reports have led to broader litigation.
This page provides general information for educational purposes only and is not a guarantee of any claim.
What Happens If You Reach Out
If you contact Lawsuit Center, the information you provide may be reviewed to better understand your situation and determine whether it may be appropriate for further attorney evaluation.
Submitting information does not guarantee that you qualify for a claim or that you will be offered representation.
Ozempic Lawsuit FAQ
What do Ozempic lawsuits allege?
These lawsuits allege that manufacturers of GLP-1 medications failed to adequately warn that use can lead to severe and persistent gastrointestinal injuries, including gastroparesis, ileus, and intestinal obstruction. A separate set of cases alleges a form of sudden vision loss called NAION.
Which medications are involved?
The litigation involves brand-name GLP-1 medications, including Ozempic, Wegovy, Mounjaro, Zepbound, Trulicity, and Saxenda. Compounded semaglutide products raise separate issues and are outside the coordinated federal litigation.
Who may qualify for a case review?
Generally, individuals who used a GLP-1 medication and experienced a serious gastrointestinal complication requiring medical treatment may potentially qualify. Gastroparesis claims generally require objective diagnostic support, such as a gastric emptying study. Vision loss claims are reviewed under the separate NAION track.
Has there been an Ozempic settlement or trial?
No. As of September 2026, no case has gone to trial and no settlement has been reached in either the gastrointestinal or the vision loss litigation. The court is deciding whether the plaintiffs' experts may testify, and that ruling will shape the trial schedule.
Is there a deadline to file?
Yes. Statutes of limitations vary by state and often run from the date of injury or from when a person reasonably connected the injury to the medication. Timing is one of the first things evaluated in a review.
Do You Recognize Your Situation?
If you experienced serious side effects after using Ozempic or a similar medication, the next step may be to request a case review.
Request a Case ReviewLawsuit Center is the intake and referral practice of David Meldofsky, a California attorney, and provides no legal advice through this site. Submitting information creates no attorney-client relationship.